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Clusters provide a better 
holistic view of type 2 
diabetes than simple 
clinical features
Although we were very pleased to see 
the strong replication of our original 
clustering study1 by John Dennis and 
colleagues,2 we disagree in part with 
their conclusions for the following 
reasons.
For the past 100 years, diabetes has 
been diagnosed by measuring one 
metabolite, glucose. However, type 2 
diabetes progression is clearly more 
complex than the contribution of 
this one variable. Diabetes develops 
when a person can no longer 
increase insulin secretion to meet 
the increased demands imposed by 
insulin resistance; therefore, including 
measures of insulin secretion and 
action in the definition of the disease is 
logical. Our cluster-based classification 
identified three severe and two milder 
forms of type 2 diabetes.1
Importantly, by extrapolating 
from type 1 diabetes on diabetic 
complications, clinicians have been 
misled to think that microangiopathic 
complications (retinopathy, neuro-
pathy, and nephropathy) develop 
together in type 2 diabetes, as seen 
in type 1 diabetes, but this is not the 
case. Retinopathy and neuropathy 
are prevalent in patients with severe 
insulin-deficient diabetes whereas 
nephropathy and fatty liver are 
more common in patients with 
severe insulin-resistant diabetes.3 
Complications associated with 
severe insulin-resistant diabetes are 
difficult to prevent solely by lowering 
blood glucose concentration in 
these patients because of their good 
metabolic control, but their insulin 
sensitivity should be improved.
Dennis and colleagues2 question the 
clinical usefulness of subclassifying 
type 2 diabetes and suggest that 
purpose-specific models with simple 
quantitative measures (ie, age at 
diagnosis) predicts changes in HbA₁c, 
and that baseline kidney function 
predicts a decline in estimated 
glomerular filtration rate (eGFR), better 
than clusters do. However, our study1 
provided a wealth of information 
beyond that of Dennis and colleagues’ 
study,2 primarily insights into the 
pathogenesis of type 2 diabetes and 
information on disease progression 
and outcomes. Nevertheless, Dennis 
and colleagues2 do provide valuable 
information on the response to 
different treatments. They evaluated 
the HbA₁c-lowering effect of three 
antidiabetic medications (metformin, 
sulfonylurea, and the insulin-sensitiser 
rosiglitazone) in the ADOPT and 
RECORD trials.4,5 In line with our 
prediction, rosiglitazone had the 
largest effect in patients with severe 
insulin-resistant diabetes. Rosiglitazone 
had no effect in patients with severe 
insulin-deficient diabetes suggesting 
that these patients might need insulin 
or a glucagon-like peptide-1 receptor 
agonist.
The study by Dennis and colleagues 
does have some limitations 
that should be considered when 
interpreting the results. First, the strict 
inclusion criteria pertaining to HbA₁c, 
fasting glucose, eGFR, BMI, and age in 
the ADOPT and RECORD trials affect 
the results. In fact, applying the same 
inclusion criteria to the ANDIS cohort 
assessed in our study1 excludes 90% of 
patients with severe insulin-deficient 
diabetes and 50% of those with severe 
insulin-resistant diabetes—many of 
the patients with the most severe 
disease. Second, although it was 
encouraging to see that the decline 
in eGFR could still be replicated, 
the absence of replication after 
adjustment for initial eGFR should 
not be over-interpreted, especially as 
this analysis had a short follow-up in 
patients with a less rapid decline in 
eGFR. Another problem ensues from 
using the nearest centroid method on 
scaled data from cohorts with different 
inclusion criteria without adjusting for 
the differences in mean and SD.
We found that the statement 
“clusters are non-aetiological, 
overlapping, highly dependent on 
the variables used to classify them, 
and cannot robustly be defined at 
an individual level”2 was not well 
substantiated. We agree that clusters 
can be partially overlapping, especially 
for individuals in the periphery of the 
clusters. However, using genetics, we 
have already shown that aetiological 
differences between clusters exist.1 
Although the severe autoimmune 
diabetes cluster, which is insulin-
deficient, is strongly associated 
with variants in the HLA locus (as in 
type 1 diabetes), no such association 
was seen for the non-autoimmune 
severe insulin-deficient diabetes cluster 
(which showed association with a 
variant in the TCF7L2 gene known to 
be associated with type 2 diabetes). The 
severe insulin-resistant diabetes cluster 
showed none of these genetic features.
Clusters can be defined on an 
individual level, as shown in our 
study.1 We have also developed a tool 
based on machine learning, which 
we think could be used in the clinic 
to estimate the probability that an 
individual patient belongs to a specific 
subgroup. This tool also identifies the 
next best match, which helps in cases 
of partially overlapping clusters. In 
our view, the clustering (which has 
been replicated almost all over the 
world [including China, Germany, and 
the USA])3,6 provides a more holistic 
view of type 2 diabetes and a better 
platform for precision medicine than 
simple clinical features.
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Authors’ reply
We thank Emma Ahlqvist and 
colleagues for their comments on our 
study,1 itself a follow-up to their original 
paper,2 which proposed five novel 
subgroups of adult-onset diabetes 
based on data-driven cluster analysis. 
We agree that our analysis was 
restricted to assessing the clinical 
utility of the clusters and did not 
assess any broader insights into the 
pathophysiology of type 2 diabetes 
or the cause of complications arising 
from the clustering approach. 
The potential insights into the 
pathophysiology of complications 
in type 2 diabetes are exciting and 
we look forward to hearing more 
about this in future publications. We 
accept that the models we propose 
are constructed to accurately predict 
clinical outcomes and do not readily 
lead to pathophysiological insights. 
In our opinion, the individual data 
from clinical trials used in our study 
offer considerable advantages over 
population-based cohorts for the 
assessment of optimal treatment 
and clinical utility. In clinical trials, 
treatment groups are randomly 
allocated and follow-up is done at 
set times and is protocol-driven, 
thereby providing robust information 
on treatment responses and clinical 
outcomes. We agree that clinical trials 
represent only a subgroup of the total 
population with diabetes, with the 
selection of specific patients having 
a disproportionate effect on some of 
the clusters; however, it is interesting 
that the proportion of individuals 
allocated to each cluster in the trial 
data were similar to those described in 
population cohorts.
In our view, precision medicine 
approaches in type 2 diabetes are 
likely to have the greatest effect on 
clinical practice if based on simple 
and reproducible clinical measures 
available in any diabetes clinic.3 The 
proposed approach based on five 
clusters2 is limited because it requires 
homoeostatic model assessment 
measures at diagnosis, based on fasting 
glucose and either fasting insulin or 
C-peptide concentration, which are 
rarely measured in the clinic. Variability 
of the precision of fasting insulin or 
C-peptide assays provide an additional 
barrier to the use of homoeostatic 
model assessment measures in the 
clinic.4,5 By contrast, our approach used 
only routine clinical measures (BMI, age 
at diagnosis, HbA1c, and renal function), 
and showed that, when modelled 
continuously, these simple measures 
outperform the more complex five 
clusters to select treatment and predict 
disease progression.
In conclusion, we think the approach 
used should depend on the outcome 
you want. Exciting new insights into 
the cause of diabetes complications 
might arise from data-driven 
approaches to classification, such as 
the five clusters proposed by Ahlqvist 
and colleagues.1 However, for practical 
approaches to personalising type 2 
diabetes care, models making use of an 
individual’s precise clinical measures 
are likely to be more useful than 
classification approaches based on 
clinical measures to assign individuals 
to subgroups. In summary, a need 
for both approaches exists because 
they have different roles. The final 
arbitrators of the most useful approach 
will be the clinicians who need to select 
treatment or predict likely outcomes.
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Lifestyle intervention 
and impaired glucose 
tolerance in the Da Qing 
study
We write in response to the report of the 
30-year results of the Da Qing Diabetes 
Prevention Outcome Study,1 which 
showed that lifestyle intervention for 
people with impaired glucose tolerance 
(IGT) is effective to curb the onset of 
type 2 diabetes and its consequences.
Because the Da Qing trial was 
initiated in the 1980s, long before 
the introduction of current WHO 
diabetes criteria, these results need 
to be interpreted cautiously. The IGT 
